- Report
- March 2024
- 188 Pages
Global
From €3242EUR$3,374USD£2,783GBP
€3602EUR$3,749USD£3,092GBP
- Report
- February 2024
- 175 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- January 2024
- 200 Pages
Global
From €4804EUR$5,000USD£4,124GBP
- Report
- August 2023
- 166 Pages
Global
From €7206EUR$7,500USD£6,186GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,237GBP
- Drug Pipelines
- July 2023
- 144 Pages
Global
From €10564EUR$10,995USD£9,069GBP
- Report
- April 2023
- 111 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- April 2023
- 129 Pages
Global
From €4564EUR$4,750USD£3,918GBP
- Report
- November 2018
- 30 Pages
China
From €2114EUR$2,200USD£1,815GBP
- Report
- June 2018
- 16 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- June 2018
- 15 Pages
Global
From €9608EUR$10,000USD£8,248GBP
- Report
- August 2023
- 91 Pages
Global
From €3500EUR$3,902USD£3,110GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,186GBP
Rosuvastatin is a drug used to treat high cholesterol and other lipid disorders. It belongs to a class of drugs known as statins, which work by blocking an enzyme in the liver that is responsible for producing cholesterol. Rosuvastatin is used to reduce the risk of heart attack, stroke, and other cardiovascular events in people with high cholesterol levels. It is also used to reduce the risk of cardiovascular events in people with type 2 diabetes and other risk factors for cardiovascular disease.
Rosuvastatin is one of the most widely prescribed statins in the cardiovascular drugs market. It is available in both generic and branded forms, and is often prescribed in combination with other drugs to treat high cholesterol. It is generally well tolerated, with few side effects.
The cardiovascular drugs market is a large and growing market, with many different drugs available to treat a variety of conditions. Rosuvastatin is one of the most popular drugs in this market, due to its effectiveness and safety profile.
Some companies in the Rosuvastatin market include AstraZeneca, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more